Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children

Dried blood spot (DBS) sampling for the purpose of therapeutic drug monitoring can be an attractive alternative for conventional blood sampling, especially in children. This study aimed to compare all costs involved in conventional sampling versus DBS home sampling in two pediatric populations: rena...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-12, Vol.11 (12), p.e0167433-e0167433
Main Authors: Martial, Lisa C, Aarnoutse, Rob E, Schreuder, Michiel F, Henriet, Stefanie S, Brüggemann, Roger J M, Joore, Manuela A
Format: Article
Language:English
Subjects:
Age Factors
Antifungal agents
Antimicrobial agents
Biology and Life Sciences
Blood
Blood tests
Child
Child, Preschool
Children
Chromatography
Comparative analysis
Cost-Benefit Analysis
Costs
Costs and Cost Analysis
Dried Blood Spot Testing - economics
Dried Blood Spot Testing - methods
Drug Monitoring
Drug stores
Drug therapy
Economic aspects
Epidemiology
Health aspects
Health care
Health Care Costs
Health sciences
Home Care Services - economics
Hospitals
Humans
Immunology
Infectious diseases
Kidney transplantation
Medicine and Health Sciences
Monitoring
Nephrology
Patients
Pediatrics
People and Places
Pharmacy
Physical Sciences
R&D
Research & development
Sampling
Therapeutic drug monitoring
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dried blood spot (DBS) sampling for the purpose of therapeutic drug monitoring can be an attractive alternative for conventional blood sampling, especially in children. This study aimed to compare all costs involved in conventional sampling versus DBS home sampling in two pediatric populations: renal transplant patients and hemato-oncology patients. Total costs were computed from a societal perspective by adding up healthcare cost, patient related costs and costs related to loss of productivity of the caregiver. Switching to DBS home sampling was associated with a cost reduction of 43% for hemato-oncology patients (€277 to €158) and 61% for nephrology patients (€259 to €102) from a societal perspective (total costs) per blood draw. From a healthcare perspective, costs reduced with 7% for hemato-oncology patients and with 21% for nephrology patients. Total savings depend on the number of hospital visits that can be avoided by using home sampling instead of conventional sampling.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0167433